Effect of Specific Mode Electroacupuncture Stimulation Combined with NGF on Dysphagia After Ischaemic Stroke: a Pilot Randomized Controlled Trial

Trial statusRecruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age18-80
SponsorThe Third Affiliated hospital of Zhejiang Chinese Medical University

About this trial

Ischemic stroke is a common clinical disease, often accompanied by dysphagia. At present, clinical treatment for patients with dysphagia after ischemic stroke is limited. The emergence of NGF has surprised the field of neurorehabilitation, but the clinical effect is not satisfactory. The main problem is that NGF is a macromolecular material with a molecular weight of 13.4 KD, which is difficult to penetrate the blood brain barrier. A large number of previous studies in our team have found that electroacupuncture with specific stimulation mode can open the blood brain barrier and induce NGF into the brain. Therefore, the purpose of this study is to investigate the effect of specific mode electroacupuncture stimulation combined with NGF treatment on patients with dysphagia after ischemic stroke and to explore the mechanism of this combination therapy to improve brain function, which creates a new method and theoretical basis for nerve rehabilitation of integrated traditional Chinese and Western medicine.

Eligibility criteria

Qualifiers

Patients with first-ever ischemic stroke confirmed by Computed Tomography (CT) and/or Magnetic Resonance Imaging (MRI);

Onset time ranged from 15 days to 180 days;

Aged 18 to 80 years old, male or female;

Dysphagia confirmed by a videofluoroscopic swallowing study (VFSS);

Disqualifiers

Patients with dysphagia before ischemic stroke onset or dysphagia not caused by ischemic stroke;

Patients with severe cognitive impairment;

Patients with severe cardiac, hepatic, and renal dysfunction, as well as severe coagulation abnormalities;

Patients with other abnormal test results who are deemed unsuitable to participate in this study by the investigator.

Trial design

Treatments tested in this trial

  • Nerver growth factor (NGF) injection
  • Placebo injection
  • EA intervention
  • Acupuncture intervention

Treatment groups

144 Participants
are divided into 4 treatment groups